Clinical trial NCT01253447: AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Official title: A Phase 2 Study of the AKT Kinase Inhibitor MK-2206 in Patients With Relapsed Refractory Acute Myelogenous Leukemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Erythroleukemia (M6a)
Adult Pure Erythroid Leukemia (M6b)
Recurrent Adult Acute Myeloid Leukemia
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
First posted: 2010-12-03
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase II trial is studying how well AKT inhibitor MK-2206 works in treating patients with relapsed or refractory acute myeloid leukemia (AML). AKT inhibitor MK-2206 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Detailed description: PRIMARY OBJECTIVES:

I. Determine the proportion of patients achieving Morphologic Complete Response (CR), Morphologic CR with incomplete count recovery (CRp) or Partial Response (PR) as best response within 3 cycles of therapy with MK-2206.

SECONDARY OBJECTIVES:

I. Describe the disease-free survival of patients that achieve CR/CRp.

II. Determine the toxicity profile of single-agent MK-2206 in this patient population.

III. To determine the biologic effects of MK-2206 on leukemia cells.

OUTLINE:

Patients receive AKT inhibitor MK-2206 orally (PO) once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.

Eligibility criteria: Inclusion Criteria:

* Patients must have histologically or cytologically confirmed AML other than acute promyelocytic leukemia (2008 World Health Organization (WHO) classification)
* Patients must have persistent or relapsing disease requiring 2nd salvage therapy (e.g. treatment for second or higher relapse or for primary refractory disease after failure of two prior treatment regimens); duration of prior complete remission \< 12 months if not refractory disease; patients with prior autologous and allogeneic hematopoietic stem cell transplantation are eligible if patients are off immunosuppression for \>1 month and have no evidence of active graft versus host disease (GVHD) except grade 1 skin GVHD
* Patients age \>= 60 years with less than two prior treatment regimens not candidates for or have refused standard chemotherapy, excluding subjects with acute promyelocytic leukemia (APL) or with favorable cytogenetic abnormalities \[inv16, t(8;21)\]
* Patient at the time of enrollment should not be a candidate for allogeneic stem cell transplantation
* The Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
* Serum creatinine or calculated creatinine clearance =\< 1.5 \* upper limit of normal (ULN) OR \>= 60 mL/min for patients with creatinine levels \> 1.5 \* institutional ULN
* Serum total bilirubin =\< 2 \* ULN OR direct bilirubin =\< ULN for patients with total bilirubin levels \> 2 \* ULN, unless elevation is thought to be due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis
* asparate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT /SGPT) =\< 2.5 \* ULN or =\< 5 \* ULN unless considered to be secondary to leukemic involvement
* Fasting serum glucose =\< 150 mg/dl
* HBA1c =\< 9%
* Female patient of childbearing potential must have a negative serum or urine pregnancy test beta- Human chorionic gonadotropin (hCG) within 72 hours prior to receiving the first dose of study medication; the effects of MK-2206 on the developing human fetus at the recommended therapeutic dose are unknown; for this reason women of childbearing potential and men must use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the patient should inform the treatment physician immediately
* Patient, or the patient"s legal representative, has voluntarily agreed to participate by giving written informed consent
* Patient is able to swallow tablets and has no surgical or anatomical condition that will preclude the patient from swallowing and absorbing oral medications on an ongoing basis

Exclusion Criteria:

* Patients may not be receiving any other investigational agents
* Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
* Active uncontrolled infection
* Systemic chemotherapy (with the exception of hydroxyurea) within 14 days (or within 5 half-lives for an investigational agent) prior to first dose of study drug, unless there is evidence of rapidly progressive disease; persistent chronic clinically significant toxicities from prior chemotherapy must not be \> grade 1
* Patients with central nervous system (CNS) involvement
* Patient has known hypersensitivity to the components of study drug or its analogs
* Uncontrolled congestive heart failure, unstable angina pectoris
* Uncontrolled cardiac arrhythmia
* History or current evidence of a myocardial infarction during the last 6 months
* corrected Q-T interval (QTc) prolongation \> 450 msec (Bazett's Formula)
* Congenitally long QT syndrome, has received any marketed or experimental compound in the last 4 weeks or 5 half lives (whichever is shorter) prior to entering the study with possible or known effects of QT prolongation
* Patient with symptomatic bradycardia, or a history of clinically significant bradyarrhythmias such as sick sinus syndrome, 2nd degree AV block (Mobitz Type 2)
* Patient with uncontrolled hypertension (i.e., i.e., sustained systolic blood pressure \>= 160 or diastolic \>= 90); patients who are controlled on antihypertensive medication will be allowed to enter the study
* Patient with poorly controlled diabetes defined as HBA1C \> 9%
* Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study
* Patient is known to be Human Immunodeficiency Virus (HIV)-positive with history of AIDS defining conditions; or CD4 cells prior to leukemia onset =\< 400 cells/mm\^3; or patients receiving antiretroviral therapy that affects CYP3A4 such as protease inhibitors, efavirenz, nevirapine, or zidovudine
* Patient has active Hepatitis B or C or active Hepatitis A

Primary outcomes:
measure: Number of Participants With a Response of CR, CRp, or PR
timeFrame: 12 weeks of treatment
measure: Number of Participants With Treatment-related Non-hematological Toxicity
timeFrame: Up to 30 days post-treatment
Secondary outcomes:
measure: Maximum Percentage Change in Apoptosis
timeFrame: Baseline to 12 courses
Other outcomes:
Locations:
city: Houston
country: United States
facility: UT MD Anderson Cancer Center
state: Texas
city: Seattle
country: United States
facility: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
state: Washington
Study officials:
affiliation: UT MD Anderson Cancer Center
name: Marina Konopleva, MD, PHD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res. 2014 Apr 15;20(8):2226-35. doi: 10.1158/1078-0432.CCR-13-1978. Epub 2014 Feb 28.